abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
nobilis or inac
intervet international bv - inaktivirana celična suspenzija serotipa a, seva b3263 / 91 ornithobacterium rhinotracheale - imunologija za aves - piščanec - za pasivno imunizacijo o pitovnih piščancih, ki jih aktivno imunizacijo ženskih pitovnih rejci na zmanjšanje okužbe z ornithobacterium rhinotracheale serotip a ko je ta zastopnik sodeluje. v situacijah na terenu se pasivna imuniteta prenese v obdobju nesnosti 43 tednov po zadnjem cepljenju brejih rejcev, kar ima za posledico trajanje pasivne imunosti v pitovnih piščancih najmanj 14 dni po izvalitvi.
tecovirimat siga
siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirusi za sistemsko uporabo - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 in 5. tecovirimat siga should be used in accordance with official recommendations.
neupopeg
dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimulants, - skrajšanje trajanja nevtropenija in pojavnost vročinskih nevtropenija pri bolnikih, zdravljenih s citotoksično kemoterapijo za malignosti (razen kronično mieloično levkemijo in mielodisplastični sindrom).
flixotide diskus 250 mikrogramov/odmerek prašek za inhaliranje, odmerjeni
gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 250 µg / 1 odmerek - flutikazon
flixotide diskus 50 mikrogramov/odmerek prašek za inhaliranje, odmerjeni
gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 50 µg / 1 odmerek - flutikazon
flixotide diskus 500 mikrogramov/odmerek prašek za inhaliranje, odmerjeni
gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 500 µg / 1 odmerek - flutikazon
flixotide diskus 100 mikrogramov/odmerek prašek za inhaliranje, odmerjeni
gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 100 µg / 1 odmerek - flutikazon
fosrenol 1000 mg peroralni prašek
shire pharmaceuticals ireland limited - lantan - peroralni prašek - lantan 1000 mg / 1 vrečica - lantanov(iii) karbonat